"Expand treatment opportunities for patients"

The Ministry of Food and Drug Safety (MFDS) said on October 20 that it had approved Livdelzi capsules, an imported orphan drug containing seladelpar lysine dihydrate, for treating adults with primary biliary cholangitis who are intolerant to ursodeoxycholic acid (UDCA) or have an inadequate response to it.


The drug works by acting on peroxisome proliferator-activated receptor delta, reducing bile acid synthesis in the liver and thereby treating primary biliary cholangitis.

MFDS Approves Livdelzi for Primary Biliary Cholangitis Treatment View original image

The MFDS designated the drug as the 52nd product under its Global Innovative Products on Fast Track (GIFT) program and conducted an expedited review to enable its rapid introduction into clinical practice.



The MFDS said, "We expect this drug to expand treatment opportunities for patients with primary biliary cholangitis who have difficulty being treated with existing therapies." It added, "We will continue to do our utmost to expand treatment opportunities for patients by expediting the review and approval of therapies whose safety and efficacy have been sufficiently verified, drawing on our regulatory science expertise.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing